LGALS1 and melanoma: The relevance of EGFR activity in this adaptive mechanism of resistance to therapy has been previously demonstrated [7]; notably, here we confirm that Gal-1 silencing prevents drug-resistant melanoma cells’ dependence on EGFR, consistent with its role as an initiator of this pathway (see Graphical Abstract).